Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

105 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to test the addition of DMXAA (now known as ASA404) to carboplatin and paclitaxel in patients with NSCLC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was designed to determine the safety, tolerability and efficacy of DMXAA in combination with carboplatin and paclitaxel in patients with locally advanced and metastatic (Stage IIIb and IV) non-small cell lung cancer. The phase Ib part of the study evaluated dose levels of DMXAA at 600 mg/m2, 1200 mg/m2 and 1800 mg/m2. In the phase II part of the study, patients were randomized to receive carboplatin and paclitaxel alone or in combination with ASA404 1200 mg/m2. An additional single-arm study was undertaken to evaluate further patients at the 1800 mg/m2 dose level.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DMXAA in combination with carboplatin and paclitaxel

Administered every 21 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DMXAA is now known as ASA404

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically confirmed non-small cell lung carcinoma designated as adenocarcinoma (including bronchoalveolar), squamous cell carcinoma or undifferentiated, mixed (adenocarcinoma and squamous) or large cell carcinoma.
2. Locally advanced Stage IIIb disease, not curable with surgery or radiotherapy, or Stage IV disease.
3. Aged ≥ 18 years of age.
4. Karnofsky performance status of ≥ 70%.
5. Life expectancy of ≥ 3 months.
6. Hematological and biochemical indices at screening comprising:

* An absolute neutrophil count of ≥ 2.0 x 109/L.
* A platelet count of ≥ 100 x 109/L.
* A hemoglobin level of ≥ 10 g/dL.
* Adequate hepatic and renal function as defined by serum bilirubin ≤ 25 µmol/L; alkaline phosphatase, alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 times the upper limit of normal if no demonstrable liver metastasis or ≤ 5 times the upper limit of normal in the presence of liver metastasis; serum creatinine ≤ 120 µmol/L.
7. At least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST).
8. Providing written informed consent and be able to comply with study assessments and follow-up.

Exclusion Criteria

1. Patients who had undergone major surgery, chemotherapy or radiation therapy (except palliative) within the previous 4 weeks.
2. A known history of hypersensitivity to carboplatin, paclitaxel or any of their excipients.
3. Previous exposure to DMXAA or other vascular targeting agents.
4. Small cell lung cancer or mixed histology.
5. Having received blood transfusions or growth factors to aid haematological recovery within 2 weeks of the scheduled baseline visit.
6. Active serious infection within 2 weeks of screening.
7. Clinically significant cardiac arrhythmias and known QTc prolongation.
8. Evidence of severe or uncontrolled systemic disease that might interfere with study participation.
9. A history of alcoholism, drug addiction or any psychiatric condition that would impair the patient's ability to comply with study procedures.
10. Pregnant or lactating women and women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test.
11. Patients should not have received within the two weeks prior to starting the study or be expected to need during the study period medications known to affect the QT interval or systemic serotonin levels.
12. Concurrent or previous malignancy of a different tumor type within 5 years of starting the study, except for adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia.
13. Clinical or radiological evidence of central nervous system metastases.
14. Evidence of any other clinically significant disorder or laboratory finding that might compromise patient safety.
15. Participation in any investigational drug study in which the study drug did not subsequently obtain a product license.

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Antisoma Research Limited

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark McKeage

Role: PRINCIPAL_INVESTIGATOR

Auckland Medical School, Auckland, New Zealand

References

Explore related publications, articles, or registry entries linked to this study.

McKeage MJ, Jameson MB; AS1404-201 Study Group Investigators. Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. J Thorac Dis. 2010 Dec;2(4):199-204. doi: 10.3978/j.issn.2072-1439.2010.02.04.1.

Reference Type DERIVED

PMID: 22263047 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AS1404-201

Identifier Type: -

Identifier Source: org_study_id